Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 200 and 300 mg BIIB 722 CL Tablet Tid and 300 and 450 mg BIIB 722 CL Tablet Bid Over 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level.

NCT02268604 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02268604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02268604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 200 and 300 mg BIIB 722 CL Tablet Tid and 300 and 450 mg BIIB 722 CL Tablet Bid Over 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2010
Completion date
Not reported
Enrollment
10 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy